Paper Details

  1. Home
  2. Paper Details

Efficacy and safety of a 12-week treatment with twice-daily aclidinium bromide in COPD patients (ACCORD COPD I).

Author: , CaractaCynthia F, D'UrzoAnthony D, Garcia GilEsther, GelbArthur F, KerwinEdward M, LakkisHassan

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Aclidinium 200 μg and 400 μg were associated with significant improvements in bronchodilation, health status, and COPD symptoms. Both doses were well tolerated.
Paper Details　
Original Abstract of the Article :
BACKGROUND: This Phase III study evaluated the efficacy and safety of twice-daily aclidinium 200 μg and 400 μg versus placebo in the treatment of moderate-to-severe COPD. METHODS: In this 12-week, double-blind, multicenter trial, patients were randomized (1:1:1) to inhaled twice-daily aclidinium 20...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.3109/15412555.2012.661492

データ提供：米国国立医学図書館（NLM）

Aclidinium Bromide: A Breath of Fresh Air in the Desert of COPD

The field of [respiratory medicine] often grapples with the challenges of chronic obstructive pulmonary disease (COPD), a debilitating condition that can be likened to a vast and unforgiving desert of respiratory distress. This study investigates the efficacy and safety of twice-daily aclidinium bromide, a long-acting muscarinic antagonist, in patients with moderate-to-severe COPD. The researchers, driven by the desire to find new ways to alleviate the symptoms and improve the quality of life for COPD patients, sought to evaluate the potential benefits of this drug, offering a potential oasis in the desert of COPD.

Aclidinium Bromide: A Breath of Fresh Air in the Desert of COPD

The researchers found that aclidinium bromide significantly improved lung function, health status, and COPD symptoms in patients with moderate-to-severe COPD, suggesting a potential for improved quality of life for those navigating this challenging condition. This is like discovering a hidden spring in the desert, offering a source of refreshment and relief for those struggling with the harsh conditions of COPD.

Navigating the Desert of COPD: Finding Relief and Resilience

This research highlights the potential benefits of aclidinium bromide as a treatment for COPD, offering a potentially more effective and well-tolerated approach to managing this debilitating condition. This is like finding a more comfortable and reliable path through the desert of COPD, providing a source of hope and resilience for those facing this challenge.

Dr.Camel's Conclusion

Aclidinium bromide offers a potential oasis in the desert of COPD, providing a breath of fresh air and a glimmer of hope for those facing this challenging condition. Further research is needed to fully understand its long-term effects and potential for improving quality of life, ensuring a more comfortable and sustainable journey through the desert of COPD.

Date :
  1. Date Completed 2013-03-29
  2. Date Revised 2022-04-08
Further Info :

Pubmed ID

22320148

DOI: Digital Object Identifier

10.3109/15412555.2012.661492

Related Literature

Article Analysis
・Effects of aclidinium oral inhalation
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.